Clinical Trial Update: Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating donor natural killer cell infusion with Rituximab, Aldesleukin, and chemotherapy in relapsed non-Hodgkin lymphoma or chronic lymphocy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Chemotherapy (chemotherapy)
• Donor natural killer cell infusion (donor-derived natural killer cells)
• Rituximab (rituximab)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2010-07-30